These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11464976)

  • 41. Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up.
    Zander AR; Schmoor C; Kröger N; Krüger W; Möbus V; Frickhofen N; Metzner B; Berdel WE; Koenigsmann M; Thiel E; Wandt H; Possinger K; Kreienberg R; Schumacher M; Jonat W
    Ann Oncol; 2008 Jun; 19(6):1082-9. PubMed ID: 18304964
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
    Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
    JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support.
    Bewick M; Chadderton T; Conlon M; Lafrenie R; Morris D; Stewart D; Glück S
    Bone Marrow Transplant; 1999 Aug; 24(4):377-84. PubMed ID: 10467326
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
    Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
    Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California.
    Damon LE; Hu WW; Stockerl-Goldstein KE; Blume KG; Wolf JL; Gold E; Cecchi GR; Irwin D; Glaspy J; Territo I; Miller W; Mason JR; Linker CA
    Biol Blood Marrow Transplant; 2000; 6(5):496-505. PubMed ID: 11063378
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Status of high-dose chemotherapy for breast cancer: a review.
    Nieto Y; Champlin RE; Wingard JR; Vredenburgh JF; Elias AD; Richardson P; Glaspy J; Jones RB; Stiff PJ; Bearman SI; Cagnoni PJ; McSweeney PA; LeMaistre CF; Pecora AL; Shpall EF
    Biol Blood Marrow Transplant; 2000; 6(5):476-95. PubMed ID: 11063377
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.
    Bulent Akinci M; Algin E; Inal A; Odabas H; Berk V; Coskun U; Uyeturk U; Isikdogan A; Aksoy S; Civelek B; Sevinc A; Buyukberber S
    J BUON; 2013; 18(2):314-20. PubMed ID: 23818340
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
    Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
    Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.
    Poole CJ; Earl HM; Hiller L; Dunn JA; Bathers S; Grieve RJ; Spooner DA; Agrawal RK; Fernando IN; Brunt AM; O'Reilly SM; Crawford SM; Rea DW; Simmonds P; Mansi JL; Stanley A; Harvey P; McAdam K; Foster L; Leonard RC; Twelves CJ;
    N Engl J Med; 2006 Nov; 355(18):1851-62. PubMed ID: 17079759
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.
    Nitz UA; Mohrmann S; Fischer J; Lindemann W; Berdel WE; Jackisch C; Werner C; Ziske C; Kirchner H; Metzner B; Souchon R; Ruffert U; Schütt G; Pollmanns A; Schmoll HJ; Middecke C; Baltzer J; Schrader I; Wiebringhaus H; Ko Y; Rösel S; Schwenzer T; Wernet P; Hinke A; Bender HG; Frick M;
    Lancet; 2005 Dec; 366(9501):1935-44. PubMed ID: 16325695
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
    Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
    Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
    Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R
    Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy.
    Bitran JD; Samuels B; Trujillo Y; Klein L; Schroeder L; Martinec J
    Clin Cancer Res; 1996 Sep; 2(9):1509-13. PubMed ID: 9816327
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
    Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
    J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or = 10 positive axillary nodes.
    Jabro G; Wazer DE; Ruthazer R; Lum R; Sklar N; Goldman D; Enegess D; Erban J
    Int J Radiat Oncol Biol Phys; 1999 May; 44(2):273-80. PubMed ID: 10760419
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
    Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
    J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.
    Diel IJ; Kaufmann M; Costa SD; Holle R; von Minckwitz G; Solomayer EF; Kaul S; Bastert G
    J Natl Cancer Inst; 1996 Nov; 88(22):1652-8. PubMed ID: 8931609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.